These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38697822)

  • 1. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
    Klabusay M; Bábková B
    Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
    Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S;
    N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
    Liu AW; Wei AZ; Maniar AB; Carvajal RD
    Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
    Chen LN; Carvajal RD
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease.
    Shildkrot Y; Wilson MW
    Curr Opin Ophthalmol; 2009 Nov; 20(6):504-10. PubMed ID: 19644367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
    Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P
    N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tebentafusp for the treatment of metastatic uveal melanoma.
    Schank TE; Hassel JC
    Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor lysis syndrome induced by tebentafusp.
    Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
    Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tebentafusp: First Approval.
    Dhillon S
    Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic uveal melanoma: The final frontier.
    Rantala ES; Hernberg MM; Piperno-Neumann S; Grossniklaus HE; Kivelä TT
    Prog Retin Eye Res; 2022 Sep; 90():101041. PubMed ID: 34999237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma.
    Lane AM; Kim IK; Gragoudas ES
    JAMA Ophthalmol; 2018 Sep; 136(9):981-986. PubMed ID: 29955797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of evidence about effectiveness of treatments for metastatic uveal melanoma.
    Augsburger JJ; Corrêa ZM; Shaikh AH
    Trans Am Ophthalmol Soc; 2008; 106():128-35; discussion 135-7. PubMed ID: 19277228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
    Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
    Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.
    Fahmy LM; Schreidah CM; McDonnell DE; Carvajal RD; Magro CM; Geskin LJ
    Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uveal melanoma: Current evidence on prognosis, treatment and potential developments.
    Gelmi MC; Jager MJ
    Asia Pac J Ophthalmol (Phila); 2024; 13(2):100060. PubMed ID: 38641203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of liver metastases from uveal melanoma: a retrospective single-center analysis.
    Yang XY; Xie F; Tao R; Li AJ; Wu MC
    Hepatobiliary Pancreat Dis Int; 2013 Dec; 12(6):602-6. PubMed ID: 24322745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the clinical management of uveal melanoma.
    Carvajal RD; Sacco JJ; Jager MJ; Eschelman DJ; Olofsson Bagge R; Harbour JW; Chieng ND; Patel SP; Joshua AM; Piperno-Neumann S
    Nat Rev Clin Oncol; 2023 Feb; 20(2):99-115. PubMed ID: 36600005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma.
    Reschke R; Enk AH; Hassel JC
    Pharmaceutics; 2024 Aug; 16(8):. PubMed ID: 39204391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study.
    Patel K; Sullivan K; Berd D; Mastrangelo MJ; Shields CL; Shields JA; Sato T
    Melanoma Res; 2005 Aug; 15(4):297-304. PubMed ID: 16034309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.